Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7487MR)

This product GTTS-WQ7487MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7487MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9902MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ6596MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DC-1728001
GTTS-WQ10418MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ5519MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ4187MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB019
GTTS-WQ135MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ11881MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ14005MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW